Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii
Gunavanthi D. Boorgula
, Sanjay Singh
, Prem Shankar
, Tawanda Gumbo
, Scott K. Heysell
, Shashikant Srivastava
Research output
:
Contribution to journal
›
Article
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Area under the Concentration-time Curve
33%
Bacterial Growth
33%
Clinical Efficacy
33%
Clinical Model
33%
Combination Regimen
100%
Death Rate
33%
Dose-response Study
33%
Effect Model
33%
Ethambutol
33%
High-dose Isoniazid
66%
Hollow Fiber Model
100%
Linear Regression
33%
Maximal Effect
33%
Minimum Inhibitory Concentration
33%
Model Regression
33%
Monotherapy
100%
Mycobacterium Kansasii
100%
Optimal Dose
33%
Pharmacokinetics-pharmacodynamics (PK-PD)
100%
Pulmonary Disease
66%
Resistance Emergence
33%
Rifampin
33%
Target Attainment
33%
Pharmacology, Toxicology and Pharmaceutical Science
Dose-Response Study
12%
Ethambutol
12%
Isoniazid
100%
Lung Disease
25%
Minimum Inhibitory Concentration
12%
Monotherapy
100%
Mycobacterium kansasii
100%
Pharmacodynamics
100%
Pharmacokinetics
100%
Rifampicin
12%